10-Q: Matinas BioPharma Reports Q1 2025 Results, Focuses on Strategic Partnerships and Cost Management

Matinas BioPharma reports a net loss for Q1 2025 and is actively seeking strategic partnerships to monetize its assets and manage its cash resources.

Summary

• Matinas BioPharma Holdings, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company is focused on securing partnerships to monetize MAT2203 and conserve cash.
• The net loss for the three months ended March 31, 2025, was $1.656 million, compared to a net loss of $5.824 million for the same period in 2024.
• Research and development expenses decreased significantly due to the pause in the MAT2203 development program.
• The company is exploring strategic options, including in-licensing assets or seeking a merger partner.
• Matinas BioPharma acknowledges substantial doubt about its ability to continue as a going concern without additional funding.
• On April 8, 2025, the company generated net proceeds of $1.520 million from the Second Closing of the sale of Preferred Stock.
• The company had cash and cash equivalents of $6.924 million and restricted cash of $250 thousand as of March 31, 2025.
• The company is prohibited from issuing common stock or equivalents until November 2025, subject to certain exceptions.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company has taken steps to reduce costs and secure funding, there are significant concerns about its ability to continue as a going concern. The focus on strategic partnerships and cost management suggests a proactive approach, but the financial challenges remain a significant risk.

Positives

• The net loss decreased significantly from $5.824 million in Q1 2024 to $1.656 million in Q1 2025.
• Research and development expenses were significantly reduced, reflecting cost-cutting measures.
• The company successfully completed a private placement of Series C Preferred Stock, raising $3.3 million in gross proceeds.
• The company recognized a gain of $294 thousand due to the change in fair value of warrant liability.

Negatives

• The company reported a net loss of $1.656 million for Q1 2025.
• The company acknowledges substantial doubt about its ability to continue as a going concern without additional funding.
• The company is prohibited from issuing common stock or equivalents until November 2025, subject to certain exceptions.
• Disclosure controls and procedures were not effective at the reasonable assurance level as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is dependent on securing partnerships, controlling operating expenses, and securing additional financing.
• The company is prohibited from issuing common stock or equivalents until November 2025, subject to certain exceptions, which limits financing options.
• The company's utilization of the At-The-Market Sales Agreement may not be viable due to market conditions.
• The company's failure to raise capital as and when needed would impact its going concern and would have a negative impact on its financial condition and its ability to pursue its business strategy.
• The company did not maintain an effective internal control environment to ensure the processing of and reporting of non-routine transactions are complete, accurate and timely, including the Company's indefinite-lived assets impairment assessment.

Future Outlook

The company expects operating expenses to be lower in the near term until additional funding is secured to support the Phase 3 registration trial for MAT2203 and advancement of the LNC platform delivery technology; the company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.

Management Comments

• Key elements of our strategy now include securing one or more partners to monetize the value of MAT2203 in the short term and raise additional non-dilutive capital through the licensing or sale of our lead LNC Platform product candidate.
• A partnership would likely seek to advance MAT2203 into Phase 3 development as quickly as possible, which could position a partner to commercialize MAT2203 upon approval and which could bring additional longer-term value to the Company and its shareholders.
• Conserving our cash resources while identifying and evaluating other strategic options for the Company, which could include the in-license of one or more assets or seeking a merger partner for the Company.

Industry Context

As a clinical-stage biopharmaceutical company, Matinas BioPharma operates in a competitive industry where securing funding and partnerships is crucial for advancing drug candidates through clinical trials and towards commercialization; the company's focus on its LNC platform and MAT2203 aligns with the industry trend of developing novel drug delivery technologies and addressing unmet medical needs.

Comparison to Industry Standards

• It is difficult to compare Matinas BioPharma's results directly to industry standards without knowing the specific therapeutic areas and stages of development of comparable companies.
• However, the company's focus on securing partnerships and managing cash is a common strategy among small to mid-sized biotech companies.
• Companies like Lipocine Inc. and Evofem Biosciences Inc. have also faced liquidity challenges and have pursued strategic alternatives, including partnerships and asset sales.
• The decrease in R&D expenses reflects a strategic shift to conserve cash, which may impact the company's ability to advance its pipeline compared to peers with more robust funding.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by cost-cutting measures and potential strategic changes.
• The company's ability to develop and commercialize its product candidates impacts patients and the broader healthcare community.
• The company's financial stability affects its relationships with suppliers and creditors.

Next Steps

• The company will seek one or more partners to monetize the value of MAT2203.
• The company will continue to identify and evaluate other strategic options, including in-licensing assets or seeking a merger partner.
• The company intends to adopt a new equity compensation plan at its 2025 Annual Meeting, pending shareholder approval.

Key Dates

Keywords

Matinas BioPharma, financial results, Q1 2025, MAT2203, LNC platform, strategic partnerships, private placement, Series C Preferred Stock, going concern, liquidity, warrants, research and development, cost management